Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

Leukemia

Volumn 22, Issue 6, 2008, Pages 1117-1124

  Quintas Cardama A ^a   Tong, W ^a   Manshouri, T ^a   Vega, F ^a   Lennon, P A ^a   Cools, J ^b   Gilliland, D G ^c,d   Lee, F ^e   Cortes, J ^a   Kantarjian, H ^a   Garcia Manero, G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ABELSON KINASE 1; CRK LIKE PROTEIN; DASATINIB; IMATINIB; NILOTINIB; NUCLEOPORIN; NUCLEOPORIN 214; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LEUKEMIA CELL LINE; LYMPHOBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 45149096506     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.80     Document Type: Article

References (30)

1. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma. D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765-767.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
3. Colleoni GW, Yamamoto M, Kerbauv J, Serafim RC, Lindsey CJ, Costa FF et al. BCR-ABL rearrangement in adult T-cell acute lymphoblastic leukemia. Am J Hematol 1996; 53: 277-278.
4. Fabbiano F, Santoro A, Felice R, Catania P, Cannella S, Majolino I. bcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia. Haematologica 1998; 83: 856-857.
5. Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153-1156.
6. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084-1089.
7. Burmeister T, Gokbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S. NUP214-ABL1 in adult T-ALL: The GMALL study group experience. Blood 2006; 108: 3556-3557.
8. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
9. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
10. Lee F, Lombardo L, Camuso A, Castaneda S, Fager K, Flefleh C et al BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005; 46: 159, (abstr 675).
11. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
13. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-3213.
14. Ravid Z, Goldblum N, Zaizov R, Schlesinger M, Kertes T, Minowada J et al. Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype. Int J Cancer 1980; 25: 705-710.
15. Heyman M, Grander D, Brondum-Nielsen K, Cederblad B, Liu Y, Xu B et al. Interferon system defects in malignant T-cells. Leukemia 1994; 8: 425-434.
16. http://www.ncbi.nlm.nih.gov/. Accessed April 24, 2007.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
18. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109: 315-322.
19. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005; 65: 3671-3681.
20. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S et al Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801.
21. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fannning S et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
22. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84: 2912-2918.
23. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin ID, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925-22928.
24. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994; 84: 1731-1736.
25. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 1991; 252: 668-674.
26. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520-2526.
27. Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 2000; 275: 35631-35637.
28. Ballerini P, Busson M, Fasola S, van den Akker J, Lapillonne H, Romana SP et al. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 2005; 19: 468-470.
29. De Keersmaecker K, Bernard R, Folens C, Mentens N, Marynen P, Fornerodet M et al. Oncogenic properties of the T-ALL-associated EML1 -ABL1 and NUP214-ABL1 fusion proteins. Blood 2006; 108: 518a (abstr 1830).
30. Kraemer D, Wozniak RW, Blobel G, Radu A. The human CAN protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm. Proc Natl Acad Sci USA 1994; 91: 1519-1523.